Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen AMJEVITA / AMGEVITA (adalimumab-atto by Year

Name: Amgen AMJEVITA / AMGEVITA (adalimumab-atto by Year (AMGN)
Creator: Amgen

AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide product sales ($M) ($M)

Quarterly Annual

Amgen AMJEVITA / AMGEVITA (adalimumab-atto: $597M in FY2025, down 21.6% from a year earlier.

Latest, FY2025

597

Period ended Dec 31, 2025

Change on a year earlier

-21.6%

761 in FY2024

History

8 years

Since FY2018

Sources

Documents cited below

Where the FY2025 figure comes from

“|| AMJEVITA ® /AMGEVITA ™ | 48 | 549 | 597 | 761 | (22%)”

Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide product sales ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	597	-21.6%	Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
FY2024	Dec 31, 2024	761	+21.6%	Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
FY2023	Dec 31, 2023	626	+36.1%	Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
FY2022	Dec 31, 2022	460	+4.8%	Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
FY2021	Dec 31, 2021	439	+32.6%	Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
FY2020	Dec 31, 2020	331	+54.0%	Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
FY2019	Dec 31, 2019	215	+1,854.5%	Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
FY2018	Dec 31, 2018	11	–	Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗

Breakdown

What makes up AMJEVITA / AMGEVITA (adalimumab-atto

Cite this data

StockData. (2026). Amgen AMJEVITA / AMGEVITA (adalimumab-atto ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-amjevita-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.